On May 13, 2024, Apellis Pharmaceuticals completed Apellis group’s USD 475 m senior secured credit facilities financing. Homburger advised Apellis with respect to all Swiss legal aspects of the transaction.

The Apellis group, centered around Apellis Pharmaceuticals, Inc., is a leading biopharmaceutical company specializing in the development and commercialization of therapeutic compounds aimed at treating a range of serious diseases. The group focuses on advancing innovative therapies targeting the complement system and is renowned for its pioneering work in ophthalmology and hematology.

The Homburger team was led by Daniel Haeberli and included Laura Müller, Yulia Shaburnykova (all Financing) and Stefan Oesterhelt (Tax).